Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Gastrointestinal Stromal Tumors 6Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Neoplasms 2Neoplasm Metastasis 2Melanoma 2Sarcoma 1Relapsed Pediatric Solid Tumor 1Mesothelioma 1Meningioma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1GIST 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1Central Nervous System Neoplasms 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1

Interventions

Tranexamic Acid 2Radiotherapy 2vistusertib 1sintilimab 1Verteporfin 1Sodium Chloride 1Sensitivity Training Groups 1Ropivacaine 1Radiosurgery 1Magnetic Resonance Spectroscopy 1Immunoenzyme Techniques 1Imatinib Mesylate 1Hyperspectral Imaging 1Hydroxyurea 1Heavy Ion Radiotherapy 1Gelclair 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Meningioma × Imatinib Mesylate × Clear all
NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

National Cancer Institute (NCI)

Phase 2 Unknown
76 enrolled
CNS

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡